Brought to you by 
GSK gets research-stage cancer project from Vernalis
27 Apr 2021
Executive Summary
Only a couple months after signing a new oncology collaboration with Servier, UK biotech Vernalis PLC has forged another deal in this therapeutic area, this time with GlaxoSmithKline, which has received an option to Vernalis' research program in cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK gets research-stage cancer project from Vernalis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice